Welcome to LookChem.com Sign In|Join Free

CAS

  • or

71233-25-5

Post Buying Request

71233-25-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

71233-25-5 Usage

Uses

1-tert-Butyl 4-Ethyl 3-Oxopiperidine-1,4-dicarboxylate is a reactant used in the synthesis of heteroaryl N-sulfonamides which demonstrate cell-death.

Check Digit Verification of cas no

The CAS Registry Mumber 71233-25-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,2,3 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 71233-25:
(7*7)+(6*1)+(5*2)+(4*3)+(3*3)+(2*2)+(1*5)=95
95 % 10 = 5
So 71233-25-5 is a valid CAS Registry Number.
InChI:InChI=1/C13H21NO5/c1-5-18-11(16)9-6-7-14(8-10(9)15)12(17)19-13(2,3)4/h9H,5-8H2,1-4H3

71233-25-5 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (E1077)  Ethyl 1-(tert-Butoxycarbonyl)-3-oxopiperidine-4-carboxylate  >98.0%(HPLC)

  • 71233-25-5

  • 200mg

  • 290.00CNY

  • Detail
  • TCI America

  • (E1077)  Ethyl 1-(tert-Butoxycarbonyl)-3-oxopiperidine-4-carboxylate  >98.0%(HPLC)

  • 71233-25-5

  • 1g

  • 990.00CNY

  • Detail
  • Alfa Aesar

  • (H64102)  Ethyl 1-Boc-3-oxopiperidine-4-carboxylate, 97%   

  • 71233-25-5

  • 250mg

  • 245.0CNY

  • Detail
  • Alfa Aesar

  • (H64102)  Ethyl 1-Boc-3-oxopiperidine-4-carboxylate, 97%   

  • 71233-25-5

  • 1g

  • 735.0CNY

  • Detail
  • Alfa Aesar

  • (H64102)  Ethyl 1-Boc-3-oxopiperidine-4-carboxylate, 97%   

  • 71233-25-5

  • 5g

  • 2940.0CNY

  • Detail

71233-25-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Ethyl N-Boc-3-Oxopiperidine-4-carboxylate

1.2 Other means of identification

Product number -
Other names 1-O-tert-butyl 4-O-ethyl 3-oxopiperidine-1,4-dicarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:71233-25-5 SDS

71233-25-5Downstream Products

71233-25-5Relevant articles and documents

PYRIMIDINE-BASED BICYCLES AS ANTIVIRAL AGENTS FOR THE TREATMENT AND PREVENTION OF HIV INFECTION

-

Page/Page column 66-67; 70, (2021/08/27)

This invention relates to pyrimidine derivatives, having HIV replication inhibiting. The present invention provides new pyrimidine compounds, designed for the treatment and prevention of HIV-mediated diseases. The invention further relates to pharmaceutical compositions and drugs contained in them. The invention also relates to the use of abovementioned compounds for the treatment and/or prevention of HIV in subjects with HIV-infection (human immunodeficiency virus) or having risk of getting HIV-infection.

PYRAZOLO[1,5-A]PYRIMIDINE-5,7-DIAMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE

-

Page/Page column 134, (2015/09/28)

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7- diamine compounds (referred to herein as "PPDA compounds") that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CDK; and to treat disorders including: disorders that are associated with CDK; disorders that result from an inappropriate activity of a cyclin-dependent kinase (CDK); disorders that are associated with CDK mutation; disorders that are associated with CDK overexpression; disorders that are associated with upstream pathway activation of CDK; disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischaemia; renal diseases; and cardiovascular disorders (including atherosclerosis). Optionally, the treatment further comprises treatment (e.g., simultaneous or sequential treatment) with a further active agent which is, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.

PYRIMIDINYL TYROSINE KINASE INHIBITORS

-

Paragraph 0084, (2014/01/08)

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 71233-25-5